A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,500 shares of SWTX stock, worth $871,955. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,500
Previous 42,000 41.67%
Holding current value
$871,955
Previous $1.58 Million 50.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$32.04 - $42.76 $560,700 - $748,300
-17,500 Reduced 41.67%
24,500 $784,000
Q2 2024

Aug 14, 2024

BUY
$36.06 - $47.62 $1.51 Million - $2 Million
42,000 New
42,000 $1.58 Million
Q3 2023

Nov 14, 2023

SELL
$23.12 - $31.38 $397,664 - $539,736
-17,200 Reduced 58.11%
12,400 $286,000
Q2 2023

Aug 14, 2023

SELL
$23.15 - $32.71 $1.56 Million - $2.2 Million
-67,200 Reduced 69.42%
29,600 $776,000
Q1 2023

May 15, 2023

SELL
$24.97 - $34.05 $1.45 Million - $1.97 Million
-57,900 Reduced 37.43%
96,800 $2.49 Million
Q4 2022

Feb 14, 2023

BUY
$21.73 - $28.72 $36,941 - $48,824
1,700 Added 1.11%
154,700 $4.02 Million
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $110,860 - $182,435
4,600 Added 3.1%
153,000 $4.37 Million
Q2 2022

Aug 15, 2022

BUY
$18.36 - $60.07 $2.72 Million - $8.91 Million
148,400 New
148,400 $3.65 Million
Q1 2022

May 16, 2022

SELL
$48.97 - $65.46 $1.66 Million - $2.23 Million
-34,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $170,560 - $242,688
3,200 Added 10.39%
34,000 $2.11 Million
Q3 2021

Nov 15, 2021

BUY
$62.66 - $88.26 $1.6 Million - $2.25 Million
25,500 Added 481.13%
30,800 $1.95 Million
Q2 2021

Aug 16, 2021

SELL
$67.45 - $85.63 $600,305 - $762,107
-8,900 Reduced 62.68%
5,300 $437,000
Q1 2021

May 17, 2021

BUY
$65.1 - $93.59 $924,419 - $1.33 Million
14,200 New
14,200 $1.05 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.22B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.